Mersana 
Welcome,         Profile    Billing    Logout  
 7 Products   9 Diseases   7 Products   3 Trials   299 News 


«123»
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    EVALUATION OF NAPI2B EXPRESSION IN A WELL ANNOTATED LONGITUDINAL TISSUE SERIES OF OVARIAN SEROUS CARCINOMAS () -  Sep 9, 2022 - Abstract #IGCS2022IGCS_630;    
    The high expression concordance rate seen suggests that NaPi2b remains consistent throughout chemotherapy treatment, supporting use of archival tissue for analysis. In this cohort , NaPi2b expression status was maintained over the treatment course in the majority of evaluated individuals reinforcing that this marker remains consistent throughout the disease course.
  • ||||||||||  XMT-2056 / Mersana, GSK
    Beyond Cytotoxic ADCs & Immunogenic Cell Death: Advancing ADCs Fully Into Immuno-oncology () -  Jul 8, 2022 - Abstract #ADCUSA2022ADC_USA_51;    
    Not yet recruiting --> Recruiting SynopsisDesign and optimization of the Immunosynthen STING agonist ADC platformExtensive characterization of the pre-clinical profile of XMT-2056, a novel, Her-2 targeted Immunosynthen ADCTranslational Research demonstrating the mechanism of an Immnosynthen ADC and its ability to activate the STING pathway in tumor cells and tumor-resident immune cells to deliver a “1-2 punch”
  • ||||||||||  emiltatug ledadotin (XMT-1660) / Mersana
    Enrollment open:  A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov) -  May 23, 2022   
    P1b,  N=166, Recruiting, 
    SynopsisDesign and optimization of the Immunosynthen STING agonist ADC platformExtensive characterization of the pre-clinical profile of XMT-2056, a novel, Her-2 targeted Immunosynthen ADCTranslational Research demonstrating the mechanism of an Immnosynthen ADC and its ability to activate the STING pathway in tumor cells and tumor-resident immune cells to deliver a “1-2 punch” Not yet recruiting --> Recruiting
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Journal:  The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b. (Pubmed Central) -  Dec 30, 2021   
    Systemic free AF-HPA and AF concentrations were observed to be low in all animal species. Finally, we describe a unique immunohistochemical reagent, generated from a chimeric construct of the therapeutic antibody, that was used to derive a target expression and efficacy relationship in a series of ovarian primary xenograft cancer models.
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Trial completion date, Trial primary completion date:  Uplift: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (clinicaltrials.gov) -  Sep 24, 2021   
    P1b/2,  N=444, Recruiting, 
    ( NCT03319628 ). Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
  • ||||||||||  XMT-1660 / Mersana, XMT-1592 / Mersana
    [VIRTUAL] Delving into XMT-1660, XMT-1592 & the Dolasynthen Platform () -  Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_161;    
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Apr 2023 Synopsis Outlining how the Dolasynthen platform is a fully homogeneous, defined platform compatible with multiple site specific bioconjugation technologies Highlighting the opportunity Dolasynthen provides to precisely create ADCs with DARs ranging from 2 to 18+ with full homogeneity Providing details on the Dolasynthen ADCs XMT-1660 targeting B7H4 and XMT-1592, targeting NaPi2b
  • ||||||||||  XMT-1592 / Mersana
    [VIRTUAL] Early Phase Fit-for-Purpose Process Development of XMT-1592 Against Accelerated Timelines () -  Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_146;    
    Synopsis Outlining how the Dolasynthen platform is a fully homogeneous, defined platform compatible with multiple site specific bioconjugation technologies Highlighting the opportunity Dolasynthen provides to precisely create ADCs with DARs ranging from 2 to 18+ with full homogeneity Providing details on the Dolasynthen ADCs XMT-1660 targeting B7H4 and XMT-1592, targeting NaPi2b Sharing a rapid tech transfer and process development strategy Exploring QbD-based optimization of conjugation unit operation Assessing development of HIC purification
  • ||||||||||  XMT-2056 / Mersana
    [VIRTUAL] XMT-2056, a Tumor-Targeted STING-Agonist ADC () -  Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_10;    
    Sharing a rapid tech transfer and process development strategy Exploring QbD-based optimization of conjugation unit operation Assessing development of HIC purification XMT-2056 is Mersana’s first Development Candidate with the Immunosynthen platform Examine how XMT-2056 induces STING activity with ~100-fold increased potency over free payload, induces tumor regressions in mice after a single low dose, and is well tolerated in repeat-dose studies in non human primates Discover Immunosynthen-based ADCs that deliver a “one-two punch” by activating the STING pathway in both tumor cells and tumor-resident immune cells
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana, XMT-1592 / Mersana
    Biomarker, Journal:  Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. (Pubmed Central) -  Sep 11, 2021   
    In this work, we demonstrated that the expression of the human NaPi2b (hNaPi2b) transporter is downregulated in the tumors of patients receiving neoadjuvant therapy and during the development of disease. The data suggest that the level of expression of the SLC34A2 gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.
  • ||||||||||  XMT-1660 / Mersana
    [VIRTUAL] XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer () -  Mar 11, 2021 - Abstract #AACR2021AACR_1533;    
    XMT-1660 and the Dolasynthen DAR-2 ADC both exhibited improved pharmacokinetics in mouse relative to the Dolaflexin DAR 12 ADC.These data indicate that XMT-1660 exhibited a superior preclinical profile to the other ADCs and more generally demonstrate the importance of DAR-ranging studies to identify the optimal antibody-drug conjugate for a given target. These results, as well as results from exploratory toxicology studies in non-human primates, strongly support the clinical development of XMT-1660.
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  Uplift: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (clinicaltrials.gov) -  Feb 15, 2021   
    P1b/2,  N=420, Recruiting, 
    Active, not recruiting --> Completed Phase classification: P1b --> P1b/2 | N=120 --> 420 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: May 2021 --> Jul 2022
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Trial completion date, Trial primary completion date:  Uplift: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (clinicaltrials.gov) -  Aug 31, 2020   
    P1b,  N=120, Recruiting, 
    Phase classification: P1b --> P1b/2 | N=120 --> 420 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: May 2021 --> Jul 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> May 2021
  • ||||||||||  Review, Journal:  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. (Pubmed Central) -  Aug 2, 2020   
    Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts...Finally, breakthroughs are occurring in the orphan triple-negative breast cancer subtype with agents targeting surface proteins. The recent results of Sacituzumab govitecan suggest substantial activity in heavily pre-treated patients and underscore the enduring relevance of antibody drug conjugates as a path towards better outcomes.
  • ||||||||||  XMT-1536 / Mersana, Adimab
    XMT1536 (NaPi2b) (STARLIGHT BALLROOM) -  Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_209;